RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2018

Sep 27, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2018-09-25

Reporting Person: Van der Ploeg Leonardus H.T. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-29	Common Stock	G	2000	$0.00	Disposed	62339	Direct
2018-09-25	Common Stock	M	21800	$4.59	Acquired	84139	Direct
2018-09-25	Common Stock	S	3686	$27.45	Disposed	80453	Direct
2018-09-25	Common Stock	S	9052	$28.88	Disposed	71401	Direct
2018-09-25	Common Stock	S	7656	$29.81	Disposed	63745	Direct
2018-09-25	Common Stock	S	5304	$30.60	Disposed	58441	Direct
2018-09-25	Common Stock	S	6102	$31.86	Disposed	52339	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-25	Employee Stock Option (Right to Buy)	$4.59	M	21800	Disposed	2025-11-16	Common Stock (21800)	Direct

Footnotes

F1: Mr. Van der Ploeg is voluntarily reporting a gift transfer of shares of common stock.

F2: On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan").

F3: This transaction was executed in multiple trades at prices ranging from $27.12 to $27.88, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff (the "Staff"), the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $28.20 to $29.19, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $29.21 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $30.21 to $31.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F7: This transaction was executed in multiple trades at prices ranging from $31.36 to $32.05, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F8: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.